Apellis Pharmaceuticals Inc Quick Ratio (APLS) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Apellis Pharmaceuticals Inc   (NASDAQ: APLS)

Apellis Pharmaceuticals Inc 's Quick Ratio

APLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 1.47 below Apellis Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Apellis Pharmaceuticals Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 808 to 1508.

Explain Quick Ratio?
How much Cash & cash equivalents APLS´s has?
What are APLS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APLS Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 61.28 % 77.06 % 47.72 % 18.59 % -20.37 %
Y / Y Cash & cash equivalent Change 13.06 % 13.36 % 20.74 % 2.76 % 9.96 %
Quick Ratio MRQ 1.47 1.47 1.76 1.91 2.09
APLS's Total Ranking # 1508 # 808 # 1151 # 155 # 955
Seq. Current Liabilities Change -12.65 % 16.15 % 41.02 % 12.72 % -4.1 %
Seq. Cash & cash equivalent Change -13.09 % -2.7 % 29.49 % 3.25 % -12.86 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 570
Overall Market # 1508


Quick Ratio Statistics
High Average Low
26.8 7.39 1.42
(Dec 31 2017)   (Dec 31 2023)




Financial Statements
Apellis Pharmaceuticals Inc 's Current Liabilities $ 276 Millions Visit APLS's Balance sheet
Apellis Pharmaceuticals Inc 's Cash & cash equivalent $ 405 Millions Visit APLS's Balance sheet
Source of APLS's Sales Visit APLS's Sales by Geography


Cumulative Apellis Pharmaceuticals Inc 's Quick Ratio

APLS's Quick Ratio for the trailling 12 Months

APLS Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 51.77 % 28.62 % 0.69 % -10.3 % -15.27 %
Y / Y Cash & cash equivalent TTM Growth 12.71 % 12.02 % 12.89 % 3.15 % -12.55 %
Quick Ratio TTM 1.63 1.76 1.98 2.11 2.19
Total Ranking TTM # 2716 # 2052 # 3125 # 2770 # 2765
Seq. Current Liabilities TTM Growth 11.02 % 16.88 % 12.09 % 4.34 % -5.92 %
Seq. Cash & cash equivalent TTM Growth 2.8 % 3.39 % 5.36 % 0.65 % 2.17 %

Quick ratio ranking by company, industry and sector >> Back to APLS Financial Strength Comparisons >> Go to Compare APLS Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q1 2026 to $276.49 millions, cumulative Quick Ratio decreased to 1.63 below the Apellis Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 383 other companies have achieved higher Quick Ratio than Apellis Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2052 to 2716.

Explain Quick Ratio?
How much Cash & cash equivalents APLS´s has?
What are APLS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 384
Healthcare Sector # 777
Within the Market # 2716


trailing twelve months Quick Ratio Statistics
High Average Low
20.01 6.8 1.58
(Sep 30 2018)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Palatin Technologies Inc   4.01 $ 10.159  Millions$ 2.536  Millions
Entrada Therapeutics Inc   3.98 $ 76.444  Millions$ 19.195  Millions
Lisata Therapeutics Inc   3.94 $ 13.060  Millions$ 3.315  Millions
Arcus Biosciences Inc   3.93 $ 822.000  Millions$ 209.000  Millions
Maravai Lifesciences Holdings Inc   3.89 $ 165.922  Millions$ 42.622  Millions
Serina Therapeutics Inc   3.87 $ 24.526  Millions$ 6.340  Millions
Aclaris Therapeutics Inc   3.85 $ 105.416  Millions$ 27.370  Millions
Genelux Corporation  3.77 $ 26.209  Millions$ 6.956  Millions
Scynexis Inc   3.73 $ 59.263  Millions$ 15.900  Millions
Gt Biopharma Inc   3.69 $ 8.923  Millions$ 2.416  Millions
Pulmatrix Inc   3.67 $ 3.324  Millions$ 0.905  Millions
Acurx Pharmaceuticals inc   3.66 $ 9.255  Millions$ 2.527  Millions
Longeveron Inc   3.63 $ 15.758  Millions$ 4.345  Millions
Reviva Pharmaceuticals Holdings Inc   3.63 $ 22.190  Millions$ 6.119  Millions
Xilio Therapeutics Inc   3.62 $ 150.333  Millions$ 41.576  Millions
United Therapeutics Corporation  3.59 $ 2,153.700  Millions$ 599.100  Millions
Vistagen Therapeutics Inc   3.55 $ 45.403  Millions$ 12.795  Millions
Hepion Pharmaceuticals Inc   3.54 $ 2.603  Millions$ 0.736  Millions
Enanta Pharmaceuticals Inc  3.53 $ 163.774  Millions$ 46.442  Millions
Rani Therapeutics Holdings Inc   3.50 $ 43.403  Millions$ 12.395  Millions
Aquestive Therapeutics Inc   3.49 $ 110.734  Millions$ 31.753  Millions
Calcimedica Inc   3.48 $ 8.164  Millions$ 2.347  Millions
Inhibitor Therapeutics Inc   3.38 $ 1.291  Millions$ 0.382  Millions
Rhythm Pharmaceuticals Inc   3.32 $ 340.625  Millions$ 102.522  Millions
Tao Synergies Inc   3.30 $ 3.646  Millions$ 1.104  Millions
Arbutus Biopharma Corp  3.14 $ 17.003  Millions$ 5.409  Millions
Bolt Biotherapeutics Inc   3.12 $ 22.892  Millions$ 7.343  Millions
Kyntra Bio Inc   3.10 $ 87.237  Millions$ 28.114  Millions
Compass Pathways Plc  3.07 $ 466.389  Millions$ 151.904  Millions
Aptevo Therapeutics Inc   3.05 $ 14.525  Millions$ 4.760  Millions

Date modified: 2026-09-26T07:32:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.